Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRA
- Development stage
- Unknown
- Lead developer
- Chugai Pharmaceutical
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MRA is a humanized monoclonal antibody designed to target and block the interleukin-6 (IL-6) receptor. By inhibiting the function of IL-6, a cytokine involved in immune responses and inflammation, MRA aims to reduce disease activity. It has been investigated for the treatment of rheumatoid arthritis (RA), demonstrating efficacy in reducing inflammatory markers and improving clinical signs of the disease.
- Other names
- humanized anti-IL-6 receptor antibodyanti-IL-6 receptor monoclonal antibodyanti-IL6 receptor monoclonal antibodyanti-IL 6 receptor monoclonal antibody
02
Targets
sIL-6R (Interleukin-6 receptor subunit alpha)
Beyond the preview
Go deeper on MRA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRA.